10x, Harvard settle genomics patent dispute with Vizgen during trial

Feb 6 (Reuters) - Genomics company 10x (TXG.O) and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware federal court.

10x and Harvard had accused Vizgen of infringing patents related to gene analysis. Vizgen countersued the company and university for allegedly breaking a contract with the U.S. National Institutes of Health by monopolizing their technology.

10x, Harvard and Vizgen told the court they would dismiss the case with prejudice, which means the claims and counterclaims cannot be refiled.

Representatives for both sides in the case said they were pleased to have resolved the dispute.

10x sued Vizgen in 2022 for allegedly infringing patents covering its Xenium In Situ gene-analysis platform. 10x licenses the patents from Harvard, and the university is also a plaintiff.

10x and Harvard requested at least $9.2 million in infringement damages, while Vizgen was seeking between $91 million and $374 million in its antitrust case, according to a court filing.

Antitrust allegations against 10x and Harvard from life sciences company Bruker (BRKR.O) remain ongoing in a related patent lawsuit.

The case is 10x Genomics Inc v. Vizgen Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00595.